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BACKGROUND. We sought to identify potential clinical variables associated with out-
comes after radium-223 therapy in routine practice.
METHODS. Consecutive non-trial mCRPC patients who received 1 dose of radium
dichloride-223 at four academic and one community urology-specific cancer centers from
May 2013 to June 2014 were retrospectively identified. Association of baseline and on-therapy
clinical variables with number of radium doses received and clinical outcomes including
overall survival were analyzed using chi-square statistics, cox proportional hazards, and
Kaplan–Meier methods. Bone Scan Index (BSI) was derived from available bone scans using
EXINI software.
RESULTS. One hundred and forty-five patients were included. Radium-223 was adminis-
tered for six cycles in 74 patients (51%). One-year survival in this heavily pre-treated
population was 64% (95%CI: 54–73%). In univariate and multivariate analysis, survival was
highly associated with receiving all six doses of Radium-223. Receipt of six doses was
associated with ECOG PS of 0–1, lower baseline PSA & pain level, no prior abiraterone/
enzalutamide, <5 BSI value, and normal alkaline phosphatase. In patients who reported
baseline pain (n¼ 72), pain declined in 51% after one dose and increased in 7%. PSA declined
50% in 16% (18/110). Alkaline phosphatase declined 25% in 48% (33/69) and 50% in 16/
69 patients. BSI declined in 17 (68%) of the 25 patients who had bone scan available at
treatment follow-up. Grade 3 neutropenia, anemia, and thrombocytopenia occurred in 4%
(n¼ 114), 4% (n¼ 125), and 5% (n¼ 123), respectively.
CONCLUSIONS. Patients earlier in their disease course with <5 BSI, low pain score, and
good ECOG performance status are optimal candidates for radium-223. Radium-223 therapy
is well tolerated with most patients reporting declines in pain scores and BSI. 77: 479–488,
2017. # 2016 Wiley Periodicals, Inc
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INTRODUCTION
Metastatic CRPC represents the lethal phenotype of
prostate cancer and will cause an estimated 27,540
deaths in 2015 in the United States [1]. Breakthroughs
in our understanding of the castration-resistance phe-
notype of prostate cancer have resulted in several novel
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agents demonstrating clinical benefits including im-
proved survival [2]. These novel agents include cyto-
toxic chemotherapy (docetaxel [3,4], cabazitaxel [5]),
androgen signaling inhibitors (abiraterone [6,7], enzalu-
tamide [8,9]), immunotherapy (sipuleucel-T [10]), and
uniquely, a bone targeted agent, radium-223 [11].
Radium-223 is an intravenously administered
bone-seeking radiopharmaceutical emitting alpha-ra-
diation with short tissue penetration depth (2–10 cells
deep or <100 microns) resulting in minimal toxicity to
bone marrow [12,13]. It is distinctly different from
samarium-153 ethylene diamine tetramethylene phos-
phonate or strontium-89 which are palliative in intent
and confer significant risk of myelosuppression. Ra-
dium-223 was tested in several early trials in CRPC
patients with painful bone metastases [13–16]. A
single-infusion study of radium-223 with doses rang-
ing from 5 to 100 kbq/kg demonstrated declines in
self-reported pain scores (Visual Analog Scale) and
analgesic use as classified by the WHO ladder
scale [15,17]. A phase 2 double blind trial randomized
122 patients to three different dose levels of radium-
223 (25, 50, and 80 kBq/kg) given every 6 weeks [18].
Only a minority of patients experienced PSA declines
by 50% or greater (6% in the 50-kBq/kg dose group).
A 50% decrease in bone alkaline phosphatase (ALP)
level was noted in substantially more patients (67% at
the 50-kBq/kg dose level). Therapy was well tolerated
with few major toxicities at all dose levels.
Subsequently, radium-223 was evaluated in the
randomized phase 3 ALSYMPCA trial, in which 921
CRPC patients with 2 symptomatic bone-only me-
tastases, either post-docetaxel or declined/ineligible
for docetaxel, were treated with either 50 kBq/kg
radium-223 (given intravenously every 4 weeks for
up to six cycles) or placebo (2:1 randomization) in
addition to best standard of care (excluding cytotoxic
chemotherapy). Stratification was by prior docetaxel
use (57% had prior docetaxel), ALP level, and
bisphosphonate use. Radium-223 significantly im-
proved the primary end-point of OS (HR 0.695, 95%CI
0.552–0.875, P¼ 0.002). Median OS was 14 months
with radium-223 and 11.2 months with placebo. The
trial confirmed the tolerable safety profile with ra-
dium, the most common adverse effects being
gastrointestinal toxicities though serious events were
similar in both arms (grade 3/4 1% with radium vs.
1% with placebo) and bone pain. Importantly, for this
patient population with implications for future explo-
rations of concurrent or sequential cytotoxic chemo-
therapy, grades 3 and 4 hematological toxicity was
uncommon (anemia 11%, neutropenia in 2%, and
thrombocytopenia in 4%) in the radium arm. Median
time to first symptomatic SRE was significantly longer
in the radium group (15.6 months vs. 9.8 months, HR
0.66, 95%CI 0.52–0.83, P¼ 0.00037) [19]. However, no
imaging was mandated in the trial and details of prior
docetaxel cumulative dose were not tracked. In a
planned subgroup analysis, the survival benefit was
maintained irrespective of prior docetaxel use albeit
with a higher frequency of grade 3 thrombocytope-
nia with radium in docetaxel treated patients (9% vs.
3% placebo) compared to docetaxel-naive patients
(3% vs. 1% placebo) [20].
Radium-223 represents a first in class therapeutic
agent in CRPC with an overall survival benefit as
monotherapy and an intriguing mode of action differ-
ent from chemotherapy and androgen signaling inhib-
itors with a relatively benign and non-overlapping
toxicity profile to those other classes. The demon-
strated overall survival benefit led to regulatory
approval of radium-223 by the FDA in 2013 for
treatment of metastatic CRPC [21]. Major challenges
in clinical practice with radium-223 include the lack of
reliable biomarkers to predict benefit in individual
patients or discern benefit during radium-223 therapy,
and the optimal timing of radium in CRPC patients’
clinical course.
Therefore, we sought to characterize the benefit of
radium-223 use in routine clinical practice in a multi-
center retrospective study and assess the clinical utility
of standard blood-based and imaging biomarkers.
METHODS
Study Design
The objectives of the retrospective study were to
identify covariates and biomarkers associated with
radium-223 use. Consecutive non-trial mCRPC
patients who received 1 dose of radium dichloride-
223 at four academic and one community urologic
oncology specific cancer centers from May 2013 to
June 2014 were included. CRPC was defined as
patients who had failed androgen deprivation therapy
and had been clinically documented to have biochem-
ical and/or radiological progression despite castrate
level of serum testosterone (<50 ng/dl). We collected
available baseline, on-treatment and post-radium-223
data including the prior treatment history, ECOG
performance score, VAS, analgesic use at baseline,
Prostate Specific Antigen (PSA), ALP, and available
bone scan images. The study was approved by the
Institutional Review Boards at the participating sites.
Automated BSI analysis: commercially available
EXINIBone version 2, developed by EXINI Diagnos-
tics AB, was used to analyze the available bone scans
and to generate automated BSI. The methodology of
the automated platform has been described
previously [22].
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Statistical Plan
Baseline data are described. Cox proportional
hazards models are used to determine prognostic
associations of baseline covariates with overall sur-
vival. Multivariable cox models were initially done
using complete cases, patients without any missing
baseline covariates. This model had a limited set of
the data (<50% of cases) and therefore multiple
imputation was used to impute all missing baseline
covariates. Five datasets were imputed and the aver-
age of the imputed values for each patient and
variable were used as a final dataset. Cox models
were repeated (univariate and multivariable) on the
multiple imputed dataset and are presented in
Table III. Overall survival Cox models for variables
from during treatment used data provided only and
were not used in the multivariable model.
Kaplan–Meier plots are provided by prior treatment
and baseline BSI.
Analysis of patient characteristics including base-
line covariates and treatment outcomes are described
using descriptive statistics classification into the num-
ber of Radium-223 treatments given. The association
between the number of Radium-223 treatments and
the continuous covariates using the ANOVA F-test for
presented means or Kruskal–Wallis test for presented
medians. Categorical covariates associations were
analyzed using Jonckheere–Terpstra test. Addition-
ally, baseline BSI was categorized into <5 and 5. The
overall survival Kaplan–Meier plot is presented.
RESULTS
One hundred and forty-four patients were included
with a mean age of 72 years (Table I). Nearly 70% had
Gleason 8 or greater in their pathology denoting
aggressive pathology. Nearly 80% had ECOG perfor-
mance score of 0 or 1. Almost half (46.5%) had prior
abiraterone acetate/enzalutamide/both, 20% each
had concurrent abiraterone or enzalutamide and 53%
TABLE I. Baseline Demographics and Clinical
Characteristics
Variable Total, N¼144
Mean age (min, max) in years 71.8 (46.1,92.2)
Race
Caucasian 128 (88.9%)
African–American 8 (5.6%)
Asian 3 (2.1%)
Other 5 (3.5%)
Study site
Fred Hutch 22 (15.3%)
Indiana university 14 (9.7%)
Roswell park cancer center 36 (25.0%)
University of Michigan cancer center 31 (21.5%)
Urology cancer center in Omaha, NE 41 (28.5%)
ECOG performance status (PS) at
baseline
0 29 (20.9%)
1 82 (59.0%)
2 22 (15.8%)
3 6 (4.3%)
Mean body mass index in kg/m2 (min,
max)
29.2 (19.4, 45.8)
Mean height in cm (min, max) 177 (156.9, 195.6)
Gleason sum
5–6 11 (7.6%)
7 35 (24.3%)
8 21 (14.6%)
9 60 (41.7%)
10 4 (2.8%)
Unknown 13 (9.0%)
Prior prostatectomy 57 (39.6%)
Prior definitive radiation therapy 27 (18.8%)
Prior salvage radiation therapy 29 (20.1%)
Prior palliative radiation therapy 57 (39.5%)
LHRH agonist or antagonist therapy 92 (63.9%)
Prior antiandrogen (e.g., bicalutamide)
for metastatic disease
54 (37.5%)
Prior androgen signaling inhibitor
therapy
Abiraterone acetate only 34 (23.6%)
Enzalutamide only 5 (3.5%)
Both abiraterone acetate and
enzalutamide
28 (19.4%)
Prior chemotherapy
Docetaxel/cabazitaxel chemotherapy 76 (52.8%)
Other chemotherapy 4 (2.8%)
Concurrent with radium-223
Abiraterone 29 (20.1%)
Enzalutamide 28 (19.4%)
WHO pain ladder scale at baseline
1 78 (54.2%)
2 30 (20.8%)
3 11 (7.6%)
Missing 25 (17.4%)
Analgesic use at baseline: Narcotics 58 (40.3%)
(Continued)
TABLE I. Continued.
Variable Total, N¼144
Bone modifying drug use at baseline 48 (33.3%)
Number of radium doses
1 15 (10.4%)
2 24 (16.7%)
3 12 (8.3%)
4 12 (8.3%)
5 7 (4.9%)
6 74 (51.4%)
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had had prior chemotherapy. Narcotic analgesics use
was 40% at baseline. Approximately half (51.4%) of all
eligible subjects in the study received all six planned
doses of radium-223. The most common reason for
receiving fewer than six doses was death. The overall
survival for the entire cohort was 15.7 months
(95% Confidence Interval: 13.0–22.5 months). In
ALSYMPCA study, the median OS in the radium-223
treated patients was 14.9 months (vs. the 11.3 months
in the control arm) which is very comparable to our
cohort.
In keeping with published trial experience with
radium-223, in our real word cohort too radium-223
therapy caused only mild cytopenias (Table II toxic-
ity). Anemia and thrombocytopenia were more com-
mon than neutropenia but were predominantly grade
1 or 2 and did not seem to differ by prior chemother-
apy status. In terms of toxicity, the post-docetaxel
group treated with radium-223 experienced more
grade 3/4 thrombocytopenia compared to placebo
(9% vs. 3%) while there was no statistical difference
between treatment and placebo in the pre-docetaxel
group, and neither were there any discernible differ-
ences in the frequencies of grade 3/4 neutropenia and
anemia versus placebo in either docetaxel-naive or
post-docetaxel subsets. Baseline ECOG PS was in
general good to excellent and largely maintained after
completion of Radium-223 though some (18.8%; 25/
133) patients experienced deterioration by the last
radium dose.
In our cohort, 9% (11/119) of the patients with data
available experienced an increase in WHO ladder
score after the first/second cycles per reported pain
scores (Fig. 1). This is termed “tumor flare” and an
increase in the score indicates worsening pain. PSA
declines by 50% or more from baseline occurred in
14% of the subjects for whom baseline and subsequent
PSA values were available (n¼ 128; Fig. 2). Serial ALP
measurements were available in 70 subjects (49%) and
35 of the 70 (50%) had 25% or greater declines while
16 subjects (23%) had reduction by 50% or more in
their total ALP levels from baseline (Fig. 3). All but
one subject with elevated ALP at baseline experienced
declines with radium-223 therapy.
As no prognostic variables currently exist for
benefit in patients receiving radium-223 therapy, we
performed a univariate and multivariable analysis of
clinical patient variables associated with overall sur-
vival (Table III). All pre-radium-223 clinical variables
were independently associated with univariate over-
all survival except prior bisphosphonate use. In
multivariate analysis, however, only elevated baseline
ALP (130mg/dl) and timing of radium-223 in the
CRPC disease course in the context of prior abirater-
one/enzalutamide and chemotherapy use were corre-
lated with overall survival. Of note, the ALSYMPCA
trial enrolled patients from June 2008 through Febru-
ary 2011 while abiraterone was FDA approved in
2011 though it was accessible through clinical trials
prior to that. Response variables measured during
radium-223 treatment were not found to be significantly
TABLE II. Hematologic Toxicity by Grade and Prior Therapy
Neutropenia (N¼ 115) Anemia (N¼ 126) Thrombocytopenia (N¼ 124)
Prior therapy Grade 0 1/2 3/4 0 1/2 3/4 0 1/2 3/4
None 33 (87%) 4 (11%) 1(3%) 5 (12%) 35 (85%) 1 (2%) 22 (54%) 16 (39%) 3 (7%)
AA/enza 12 (86%) 1 (7%) 1 (7%) 1 (6%) 15 (94%) 0 (0%) 9 (60%) 6 (40%) 0 (0%)
Chemo 24 (89%) 2 (7%) 1 (4%) 1 (4%) 23 (85%) 3 (11%) 18 (67%) 7 (26%) 2 (7%)
ChemoþAA/enza 32 (89%) 3 (8%) 1 (3%) 1 (2%) 39 (93%) 2 (5%) 24 (59%) 16 (39%) 1 (2%)
Total 101 (88%) 10 (9%) 4 (4%) 8 (6%) 112 (89%) 6 (5%) 73 (59%) 45 (36%) 6 (5%)
P-value 0.76 0.065 0.53
AA, abiraterone acetate; Enza, enzalutamide; Chemo, chemotherapy.
Fig. 1. Greatest change in WHO pain ladder step stratified by
baseline WHO pain ladder step.
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associated with overall survival. Overall survival by
pre-treatment group is displayed in Figure 4. The
number of radium-223 doses received was associated
with ECOG performance status at baseline, extent of
prior therapy and ALP elevation (Table IV).
A subgroup of 66 (46%) patients had a baseline
bone scan and was retrospectively analyzed for auto-
mated BSI assessment. No significant differences were
observed in baseline characteristics of patients with
bone scans versus without. Median baseline auto-BSI
was 2.4 (range: 0.01–33.2). A smaller subset of patients
(n¼ 25) had bone scans available at both baseline and
at 24-week treatment. Change in BSI was evaluated in
these patients. Seventeen (68%) of the 25 patients
showed a decrease in auto-BSI from baseline. Consis-
tent with previous studies, baseline BSI values were
significantly associated with overall survival (Fig. 5).
Due to the ad hoc BSI analysis on the available bone
scans at treatment follow-up, the change in BSI is only
reportable on 25 of the 66 patients with baseline bone
scans. BSI declined in most of these patients who
received six doses of radium-223. An illustrative
example is shown in Figure 6.
DISCUSSION
With the inherent limitations of a retrospective
chart review study, our multi-center cohort of mCRPC
patients treated with radium-223 outside of trials is
the largest group described to date with data measur-
ing the real world impact of radium-223. The
participating sites are cancer centers experienced in
radium-223 therapy with a mix of academic and
community practices.
Patients who had had no chemotherapy prior to
radium had longer overall survival (OS) compared to
those who had had chemotherapy. This likely reflects
less advanced and less intractable disease. Consistent
with this, more of those patients who received all six
Fig. 2. Maximum PSA decline from baseline with radium-223 therapy (N¼ 128).
Fig. 3. Maximum decrease in alkaline phosphatase from baseline
with radium-223 therapy (N¼ 70).
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planned radium doses had ECOG performance statuses
of 0 or 1 versus those who received one or two doses.
Our analysis presents a few clear inferences. Pain
relief from symptomatic bone metastases is a concrete
benefit of radium-223 therapy. The decline in pain
index and its individual components (VAS score and
WHO ladder level) in most patients offers meaningful
palliation from bone pain. There have been sugges-
tions of a flare in pain, PSA or bone scan seen in up to
25% of pts with the initial doses of radium-223 in
early studies akin to the LHRH flare effect, flare with
ASIs or the taxane PSA surge [13,23–25]. The variabil-
ity in analgesic use, missing data and small numbers
with the first two cycles, probably account for the
difference in reported frequency of the flare response
with radium in our group of patients.
TABLE III. Overall Survival Models
Clinical covariates prior to treatment
Univariate models hazard
ratio (95%CI) P-value
Multivariable model hazard
ratio (95%CI) P-value
Age (per year increase) 1.16 (0.99, 1.35) 0.07
Height (per 10 cm increase) 0.61 (0.40, 0.93) 0.02
BMI (ref: 25–30) kg/m2 0.04
<25 vs. 25–30 1.51 (0.77, 2.96)
30–35 vs. 25–30 0.40 (0.16, 1.02)
35þ vs. 25–30 0.77 (0.30, 1.97)
ECOGPS 2/3 vs. 1/2 2.77 (1.47, 5.22) 0.002
Baseline WHO pain score 0.03
2 vs. 1 1.94 (1.01, 3.72)
3 vs. 1 2.73 (1.17, 6.40)
Prior therapy 0.0006 0.0008
None Ref Ref
Abiraterone/enzalutamide 0.93 (0.25, 3.45) 0.54 (0.14, 2.08)
Chemotherapy 1.50 (0.59, 3.77) 1.77 (0.70, 4.48)
ChemoþAbi/enza 4.05 (1.87, 8.79) 3.53 (1.63, 7.67)
Alkaline phosphatase at baseline
130 vs. <130 2.85 (1.57, 5.15) 0.0006 3.13 (1.67, 5.86) 0.0004
Log baseline PSA 1.30 (1.12, 1.50) 0.0004
Prior bisphosphonate/denosumab use
Yes vs. no 1.18 (0.65, 2.14) 0.60
Baseline BSI (log scale)
Study institution – 0.26
During therapy covariates
WHO pain ladder step change during therapy 0.47
Step increased vs. no change 1.22 (0.44, 3.43)
Step decreased vs. no change 2.05 (0.63, 6.67)
Hematologic toxicity 0.83
Grade 3/4 vs. none 0.53 (0.06, 4.65)
Grade 1/2 vs. none 0.54 (0.07, 4.01)
25% decrease in alkaline phosphatase from
baseline during rad therapy
No vs. yes 1.14 (0.44, 2.96) 0.79
PSA response during Rad therapy?
Yes vs. no 0.54 (0.19, 1.52) 0.24
Fig. 4. Overall survival stratified by prior treatments received.
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PSA declines were noted in a minority of patients
consistent with previously published data on impact
of radium-223 therapy on PSA and its mechanism of
action which is for the most part directed at the bone
tumor microenvironment rather than at prostate
cancer cells specifically. PSA values are therefore hard
to interpret on radium-223 therapy and PSA changes
should not direct radium-223 therapy decisions or
duration.
ALP (total or bone-specific) has been explored as a
potential biomarker for radium-223. In the early
published experience, patients with elevated total
ALP at baseline had robust declines but not those
with normal ALP [13]. In an ad hoc analysis of ALP
levels in ALSYMPCA patients, declines in ALP were
correlated with prolonged survival. In our dataset,
only half experienced declines but of those who had
TABLE IV. Association Between Clinical Variables and Number of Radium-223 Doses
Baseline
1–2 treatments of
radium-223
3–4 treatments of
radium-223
5–6 treatments of
radium-223 P-value
N 39 24 81
Mean age 73.5 (8.6) 72.0 (10.1) 71.0 (10.2) 0.43
Height (per 10 cm increase) 175.5 (7.8) 177.6 (8.9) 177.6 (6.2) 0.31
BMI 0.19
<25 13 (33%) 5 (21%) 20 (25%)
25–30 15 (38%) 6 (25%) 23 (28%)
30–35 7 (19%) 7 (29%) 24 (30%)
35þ 4 (10%) 6 (25%) 14 (17%)
ECOG performance status
0/1 24 (62%) 21 (88%) 70 (86%) 0.005
2/3 15 (38%) 3 (13%) 11 (14%)
PSA baseline median (IQR) 188.7 (42–517) 172.5 (58–470) 20.7 (4–97) <0.0001
Prior treatment 0.0003
None 7 (18%) 7 (29%) 32 (40%)
Abiraterone/enzalutamide only 4 (10%) 5 (21%) 9 (11%)
Chemotherapy only 5 (13%) 1 (4%) 25 (31%)
Chemotherapy and abiraterone/enzalutamide 23 (59%) 11 (46%) 15 (19%)
Bisphosphonates use within 1 year of radium-223: Yes 12 (31%) 9 (38%) 27 (33%) 0.88
Baseline WHO pain score 0.06
1 22 (56%) 17 (71%) 58 (72%)
2 8 (21%) 7 (29%) 19 (23%)
3 9 (23%) 0 (0%) 4 (5%)
Alkaline phosphatase at baseline (N¼ 89): Elevated (i.e.,
130)
22 (56%) 9 (38%) 25 (31%) 0.01
On-treatment changes
Toxicity
None 1 (4%) 2 (10%) 1 (1%) 0.43
Grade 1/2 21 (81%) 19 (90%) 68 (86%)
Grade 3/4 4 (15%) 0 10 (13%)
PSA response during radium-223 therapy (N¼ 112) 2 (7%) 1 (5%) 15 (19%) 0.06
25% decrease in alkaline phosphatase from baseline
during radium-223 therapy (N¼ 71): Yes
4 (57%) 4 (50%) 27 (49%) 0.75
Change in pain level during therapy by VAS (N¼ 117) 0.22
Pain decreased 3 (8%) 0 (0%) 4 (5%)
No change 35 (90%) 22 (92%) 69 (85%)
Pain increased 1 (3%) 2 (8%) 8 (10%)
Median survival (95%CI) 2.6 (2.4–6.2) 7.9 (5.2–NR) 15.7 (15.7–22.5)
Fig. 5. Overall survival stratified by baseline BSI (N¼ 65).
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elevated values at baseline, all but one patient experi-
enced a decrease. Unanswered questions remain:
How specific a measure of tumor burden in bone is
ALP in mCRPC patients? How predictive are changes
in ALP? How does this marker perform in the large
number of mCRPC patients whose total ALP is within
the normal range at baseline? A panel of bone
turnover markers may potentially better measure
impact of radium-223 on bone and bone metastases.
Bone Scan Index (BSI) as a semi-quantitative assess-
ment of bone scintigraphy has shown clinical validity
as an imaging biomarker associated with overall
survival in other contexts [26]. To our knowledge, this
is the first study to explore the clinical context of BSI
in metastatic prostate cancer patients treated with
radium-223. Baseline BSI deserves to be further
studied in future prospective trials of radium-223.
More than half of the patients in our cohort had
received prior cytotoxic chemotherapy. Impact of
prior chemotherapy on radium-223 toxicity and bene-
fit was analyzed in patients on the ALSYMPCA trial
in a pre-specified manner. Patients who had received
docetaxel previously (57%) as well as those docetaxel
naive (43%) derived an overall survival benefit from
Fig. 6. Illustrative on-treatment BSI change in a patient before and after six cycles of radium-223. The red color represents the hotspots
detected by EXINI software and included in the BSI-assessment.
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radium-223 with very similar hazard ratios and
confidence intervals [20]. The bone marrow toxicity
with radium-223 is remarkably modest and lends
itself very well to combination therapy with agents
from other classes including cytotoxic chemotherapy.
Our post-radium follow-up data collection was lim-
ited and did not permit analysis of a possible radium-
223 impact on toxicity from subsequent therapies or
incidence of secondary neoplasms.
An intriguing hypothesis based on the stated
mechanism of action for radium-223 is that radium is
ideally dosed on height, possibly a more accurate
proxy for skeletal mass in a patient than body weight.
If this hypothesis is true, obese patients are being
over-treated currently (possibly experiencing more
toxicities) and taller patients are being under-treated
(possibly resulting in inferior clinical benefit and
outcomes). In our univariate and multivariate analy-
ses of our limited cohort, there is no evidence to
support the former inference and no way to test the
latter. The reasoning behind such a hypothesis may
merit further prospective evaluation.
What emerges from our dataset is the importance
of considering radium-223 early on in patients CRPC
disease course where patients are more likely to
receive all six planned cycles. The absence of a control
arm limits our conclusions regarding the independent
impact of radium-223 on the survival of our patients
included in the study and it is probable that receipt of
all six cycles is merely a surrogate for known good
prognostic factors in CRPC such as better perfor-
mance status. The lack of LDH values for a significant
number of patients in this cohort made estimation of a
predicted overall survival with tools such as the
Halabi nomogram impossible but the OS was very
comparable to data from radium-223 trials such as
ALSYMPCA which also had docetaxel-untreated and
treated CRPC patients.
Ongoing studies are exploring higher doses and
longer courses of radium-223 treatment in prostate
cancer (NCT02023697). One could safely surmise that
utilizing radium-223 early on in the course of castra-
tion resistant prostate cancer before ECOG PS declines
to two or worse is a reasonable and effective strategy
given that dose number is key to deriving maximal
benefit. Post-radium chemotherapy could be expected
to be unhampered given the mild and reversible
myelosuppressive effect of radium but awaits further
data. Assessment of long-term complications such as
secondary malignancies and if they are heightened by
early radium-223 use deserves long-term prospective
studies. Ongoing clinical trials are examining combi-
nations of radium-223 with ASIs and no doubt, these
will refine the role of radium-223 in the quickly
burgeoning options for treatment of CRPC.
CONCLUSIONS
In this multisite retrospective study, patients who
received radium-223 in CRPC prior to cytotoxic
chemotherapy had longer survival as did those with
elevated serum ALP. Radium-223 therapy is well
tolerated in routine clinical practice with most
patients experiencing declines in pain scores and BSI.
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